← Leaderboards
Mark Yarchoan
Johns Hopkins University
$3,378,705
Attributed
$5,464,219
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2022–25$2.5M$1.9M$1.3M$625K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$5,464,219 · 3
By mechanism
R01$5,464,219 · 3
Top collaborators
- Paul Glyndwr Thomas4 shared
- Won Jin Ho2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Michael S Torbenson$5,937,223
- Barbara Stauch Slusher$18,499,514
- Dung T Le$5,608,820
- Ben H Park$14,510,999
- Eric Hutton Raabe$804,830
Others in their field
Other Rising Stars on “Cytometry”
- Li Liang · University Of California-Irvine$7,511,446
- Lisa Wagar · University Of California-Irvine$6,349,785
- Christine O'Connell · H. Lee Moffitt Cancer Ctr & Res Inst$5,494,823
- Michael P Weiner · Abbratech, Inc.$4,404,422
- Pei-Hsun Wu · Johns Hopkins University$4,251,799
- Martin Pule · University College London$3,627,871
Research focus
CytometryImmunotherapyPre-Clinical ModelTumorNovel Therapeutic InterventionImmune ResponseMalignant Neoplasm Of LiverPathway InteractionsT-LymphocyteImmuneSystemic TherapyResponseMalignant NeoplasmsChildChimera OrganismImmune Checkpoint InhibitorGenomic SignatureExonsFibrolamellar Hepatocellular CarcinomaImmune ResistanceCancer TherapyAnti-Tumor Immune ResponseBloodAffect
Grant awards (8)
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma$717,369
R01 · FY2025 · CA · contact PI
Neoadjuvant Immunotherapy Platform Study Reveals Mechanisms of Response in Hepatocellular Carcinoma (HCC)$673,789
R01 · FY2025 · CA · contact PI
Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)$643,101
R01 · FY2025 · CA · contact PI
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma$681,501
R01 · FY2024 · CA · contact PI
Neoadjuvant Immunotherapy Platform Study Reveals Mechanisms of Response in Hepatocellular Carcinoma (HCC)$662,037
R01 · FY2024 · CA · contact PI
Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)$650,089
R01 · FY2024 · CA · contact PI
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma$703,025
R01 · FY2023 · CA · contact PI
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma$733,308
R01 · FY2022 · CA · contact PI